Omeros Corporation Announces FDA Approval of Omidria for Use in Pediatric Patients

SEATTLE--(BUSINESS WIRE)--Dec. 12, 2017-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news